Sanofi CEO Finally Scores With $11.6B Buyout of Biogen's Spinoff Bioverativ Post author:Sam Post published:January 21, 2018 Post category:BioPharma The deal has Sanofi paying $105 per share in cash. Source: BioSpace You Might Also Like Say “No” the Right Way: How Declining a Job Offer can Advance Your Career March 1, 2018 BioAmber Announces Year End Operational And Financial Results For 2016 March 16, 2017 FDA Calls Novartis' Melanoma Combo Drug a Breakthrough October 22, 2017
